An overview of current treatment strategies for β-thalassemia

Maria Domenica Cappellini, Vip Viprakasit, Ali T. Taher

Research output: Contribution to journalArticle

Abstract

Introduction: At least 40,000 people per year worldwide are born with β-thalassemia. Patients with β-thalassemia major are reliant on regular red blood cell transfusions for survival from a young age. For those with β-thalassemia intermedia or hemoglobin (Hb) E/β-thalassemia, symptoms range from mild clinical presentation to a more severe phenotype and patients are not necessarily transfusion-dependent.Areas covered: Here, β-thalassemia treatment strategies including transfusion, splenectomy, fetal hemoglobin induction, hematopoietic stem-cell transplantation, in addition to potential future treatment options, are reviewed. Approaches for the monitoring and management of complications are also described.Expert opinion: The most important advances in the treatment of transfusion-dependent β-thalassemia major patients since the advent of iron chelation therapy are the introduction of oral iron chelators in addition to technologies for the direct measurement of iron in organs. For non-transfusion-dependent patients with β-thalassemia intermedia or HbE/β-thalassemia, recent studies have highlighted the significance of iron overload-related complications and the increase in incidence with advancing age, prompting the development of much-needed clinical treatment guidelines. Future research should focus on improving the treatment of β-thalassemia major patients to further extend survival and quality of life, and continued identification of β-thalassemia intermedia or HbE/β-thalassemia patients who may benefit from transfusion and iron chelation therapy.

Original languageEnglish
Pages (from-to)665-679
Number of pages15
JournalExpert Opinion on Orphan Drugs
Volume2
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Thalassemia
beta-Thalassemia
Iron
Chelation Therapy
Therapeutics
Hemoglobin E
Fetal Hemoglobin
Erythrocyte Transfusion
Iron Overload
Hematopoietic Stem Cell Transplantation
Expert Testimony
Splenectomy
Chelating Agents
Cell Survival
Quality of Life
Guidelines
Technology
Phenotype
Survival
Incidence

Keywords

  • Chelation
  • Complications
  • Hematopoietic stem-cell transplantation
  • Hydroxyurea
  • Iron
  • Transfusion
  • β-thalassemia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

An overview of current treatment strategies for β-thalassemia. / Cappellini, Maria Domenica; Viprakasit, Vip; Taher, Ali T.

In: Expert Opinion on Orphan Drugs, Vol. 2, No. 7, 2014, p. 665-679.

Research output: Contribution to journalArticle

Cappellini, Maria Domenica ; Viprakasit, Vip ; Taher, Ali T. / An overview of current treatment strategies for β-thalassemia. In: Expert Opinion on Orphan Drugs. 2014 ; Vol. 2, No. 7. pp. 665-679.
@article{ec137b03a0884224a0a15d0be2383f5a,
title = "An overview of current treatment strategies for β-thalassemia",
abstract = "Introduction: At least 40,000 people per year worldwide are born with β-thalassemia. Patients with β-thalassemia major are reliant on regular red blood cell transfusions for survival from a young age. For those with β-thalassemia intermedia or hemoglobin (Hb) E/β-thalassemia, symptoms range from mild clinical presentation to a more severe phenotype and patients are not necessarily transfusion-dependent.Areas covered: Here, β-thalassemia treatment strategies including transfusion, splenectomy, fetal hemoglobin induction, hematopoietic stem-cell transplantation, in addition to potential future treatment options, are reviewed. Approaches for the monitoring and management of complications are also described.Expert opinion: The most important advances in the treatment of transfusion-dependent β-thalassemia major patients since the advent of iron chelation therapy are the introduction of oral iron chelators in addition to technologies for the direct measurement of iron in organs. For non-transfusion-dependent patients with β-thalassemia intermedia or HbE/β-thalassemia, recent studies have highlighted the significance of iron overload-related complications and the increase in incidence with advancing age, prompting the development of much-needed clinical treatment guidelines. Future research should focus on improving the treatment of β-thalassemia major patients to further extend survival and quality of life, and continued identification of β-thalassemia intermedia or HbE/β-thalassemia patients who may benefit from transfusion and iron chelation therapy.",
keywords = "Chelation, Complications, Hematopoietic stem-cell transplantation, Hydroxyurea, Iron, Transfusion, β-thalassemia",
author = "Cappellini, {Maria Domenica} and Vip Viprakasit and Taher, {Ali T.}",
year = "2014",
doi = "10.1517/21678707.2014.918503",
language = "English",
volume = "2",
pages = "665--679",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - An overview of current treatment strategies for β-thalassemia

AU - Cappellini, Maria Domenica

AU - Viprakasit, Vip

AU - Taher, Ali T.

PY - 2014

Y1 - 2014

N2 - Introduction: At least 40,000 people per year worldwide are born with β-thalassemia. Patients with β-thalassemia major are reliant on regular red blood cell transfusions for survival from a young age. For those with β-thalassemia intermedia or hemoglobin (Hb) E/β-thalassemia, symptoms range from mild clinical presentation to a more severe phenotype and patients are not necessarily transfusion-dependent.Areas covered: Here, β-thalassemia treatment strategies including transfusion, splenectomy, fetal hemoglobin induction, hematopoietic stem-cell transplantation, in addition to potential future treatment options, are reviewed. Approaches for the monitoring and management of complications are also described.Expert opinion: The most important advances in the treatment of transfusion-dependent β-thalassemia major patients since the advent of iron chelation therapy are the introduction of oral iron chelators in addition to technologies for the direct measurement of iron in organs. For non-transfusion-dependent patients with β-thalassemia intermedia or HbE/β-thalassemia, recent studies have highlighted the significance of iron overload-related complications and the increase in incidence with advancing age, prompting the development of much-needed clinical treatment guidelines. Future research should focus on improving the treatment of β-thalassemia major patients to further extend survival and quality of life, and continued identification of β-thalassemia intermedia or HbE/β-thalassemia patients who may benefit from transfusion and iron chelation therapy.

AB - Introduction: At least 40,000 people per year worldwide are born with β-thalassemia. Patients with β-thalassemia major are reliant on regular red blood cell transfusions for survival from a young age. For those with β-thalassemia intermedia or hemoglobin (Hb) E/β-thalassemia, symptoms range from mild clinical presentation to a more severe phenotype and patients are not necessarily transfusion-dependent.Areas covered: Here, β-thalassemia treatment strategies including transfusion, splenectomy, fetal hemoglobin induction, hematopoietic stem-cell transplantation, in addition to potential future treatment options, are reviewed. Approaches for the monitoring and management of complications are also described.Expert opinion: The most important advances in the treatment of transfusion-dependent β-thalassemia major patients since the advent of iron chelation therapy are the introduction of oral iron chelators in addition to technologies for the direct measurement of iron in organs. For non-transfusion-dependent patients with β-thalassemia intermedia or HbE/β-thalassemia, recent studies have highlighted the significance of iron overload-related complications and the increase in incidence with advancing age, prompting the development of much-needed clinical treatment guidelines. Future research should focus on improving the treatment of β-thalassemia major patients to further extend survival and quality of life, and continued identification of β-thalassemia intermedia or HbE/β-thalassemia patients who may benefit from transfusion and iron chelation therapy.

KW - Chelation

KW - Complications

KW - Hematopoietic stem-cell transplantation

KW - Hydroxyurea

KW - Iron

KW - Transfusion

KW - β-thalassemia

UR - http://www.scopus.com/inward/record.url?scp=84903306695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903306695&partnerID=8YFLogxK

U2 - 10.1517/21678707.2014.918503

DO - 10.1517/21678707.2014.918503

M3 - Article

AN - SCOPUS:84903306695

VL - 2

SP - 665

EP - 679

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 7

ER -